Skip to main content
AmgenRevenue

AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

Source: Autobound Signal API · 83 signals tracked for Amgen · updated

Get Amgen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Amgen this week? Use Autobound signals for amgen.com.

What happened

Amgen reported total product sales of $9,883 million for the third quarter of 2026.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

THOUSAND OAKS, Calif. , Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the third quarter of 2026. "Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise," said Robert A. Bradway, chairman and chief executive officer. "The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen's ability to deliver durable growth well into the next decade." Key results include: References in this release to "non-GAAP" measures, measures presented "on a non-GAAP basis," and "free cash flow" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. Refer to Non-GAAP Financial Measures below for further discussion. Product Sales Performance General Medicine Rare Disease Inflammation Oncology Established Products Product Sales Detail by Product and Geographic Region $Millions, except percentages Q3 '26 Q3 '25 YOY Δ U.S ROW TOTAL TOTAL TOTAL Repatha ® $ 666 $ 419 $ 1,085 $ 794 37 % EVENITY ® 557 194 751 541 39 % Prolia ® 409 223 632 1,139 (45 %) TEPEZZA ® 441 85 526 560 (6 %) KRYSTEXXA ® 419 - 419 320 31 %...

Keep reading with a free account

The rest of this article, and every signal for Amgen, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Revenue

What this signalsRevenue results often set the next budget cycle.

Amount named
$9.9B
Location
Thousand Oaks, California, United States

The full record

From the Signal API record

Numbers

Amount named in the story
$9.9B

Details

Ticker
NASDAQ:AMGN

Extraction

Confidence
95%
Detected
Nov 3, 2026
signal_type
news
signal_subtype
has_revenue

Use this data

Get every revenue signal for Amgen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”

  2. Send it to your own tools

    The Signal API returns revenue signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/47a8aa0b-1b6a-1858-1a0a-a54a62ecba4b returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.

{
  "signal_id": "47a8aa0b-1b6a-1858-1a0a-a54a62ecba4b",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-11-03T21:01:00+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/amgen-reports-third-quarter-2026-financial-results-302928131.html",
    "title": "AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS",
    "ticker": "NASDAQ:AMGN",
    "excerpt": "THOUSAND OAKS, Calif. , Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the third quarter of 2026. \"Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise,\" said Robert A. Bradway, chairman and chief executive officer. \"The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen's ability to deliver durable growth well into the next decade.\" Key results include: References in this release to \"non-GAAP\" measures, measures presented \"on a non-GAAP basis,\" and \"free cash flow\" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. Refer to Non-GAAP Financial Measures below for further discussion. Product Sales Performance General Medicine Rare Disease Inflammation Oncology Established Products Product Sales Detail by Product and Geographic Region $Millions, except percentages Q3 '26 Q3 '25 YOY Δ U.S ROW TOTAL TOTAL TOTAL Repatha ® $ 666 $ 419 $ 1,085 $ 794 37 % EVENITY ® 557 194 751 541 39 % Prolia ® 409 223 632 1,139 (45 %) TEPEZZA ® 441 85 526 560 (6 %) KRYSTEXXA ® 419 - 419 320 31 %...",
    "summary": "Amgen reported total product sales of $9,883 million for the third quarter of 2026.",
    "location": "Thousand Oaks, California, United States",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS352354/AMGEN-LOGO-V2.jpg?id=OA3054432&p=facebook",
    "confidence": 0.95,
    "published_at": "2026-11-03T21:01:00Z",
    "location_data": [
      {
        "city": "Thousand Oaks",
        "state": "California",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "THOUSAND OAKS, Calif. , Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the third quarter of 2026.",
    "amount_normalized": 9883000000
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.